Navigation Links
Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
Date:5/8/2013

uring and commercialization challenges that have impeded other personalized cancer immunotherapies. Automated processes allow a single facility to serve all of North America and can be used to treat any cancer or infectious disease with the same manufacturing process and equipment.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos´ most advanced product candidate AGS-003 has initiated a Phase 3 study for the treatment of mRCC, and the Company plans to have data from its Phase 2b study of AGS-004 for the treatment of HIV in late 2013. For more information about Argos Therapeutics, visit www.argostherapeutics.com.

Contact:

The Ruth Group
Caitlin Cox (media)
ccox@theruthgroup.com 
(646) 536-7033

Nicole Greenbaum (investors)
ngreenbaum@theruthgroup.com 
(646) 536-7009

Argos Therapeutics
Jeff Abbey (partners)
jabbey@argostherapeutics.com 
(919) 287-6308

 


'/>"/>
SOURCE Argos Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
2. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
3. Collegium Announces Results of Chronic Pain Patient Survey - Confirms Significant Unmet Medical Need for a Differentiated, Abuse-Deterrent, Extended-Release Opioid
4. New CDC Study Confirms Effectiveness of UV-C Disinfection in Reducing Harmful Pathogens for Hospitals
5. Lilly Confirms Date and Conference Call for First-Quarter 2013 Financial Results Announcement
6. Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%
7. Perrigo Confirms FDA Approval For Testosterone Gel 1%
8. New Analysis Confirms Albumin Preserves Kidney Function and Improves Survival in Common Abdominal Infection of Liver Disease
9. Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Sciences Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma
10. Quest Diagnostics Confirms Investor Day on November 16
11. TUV Rheinland Confirms Apparent Fraud in Mislabeling of DRX Products Manufactured by HTRD and Excite Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014  Avanir Pharmaceuticals, ... the U.S. Food and Drug Administration (FDA) has ... Drug Application (NDA) for AVP-825. AVP-825 is an ... powder delivered intranasally utilizing a novel Breath Powered ... Response letter, and consistent with the preliminary feedback ...
(Date:11/26/2014)... N.Y. , Nov. 26, 2014  BioScrip ® , Inc. ... Smith , President and Chief Executive Officer, will present at the ... , , , Date: , , , Wednesday, ... , 2:50 p.m. EST , , , , Location: , ... About BioScrip, Inc. BioScrip, ...
(Date:11/26/2014)... Nov. 26, 2014  Aridis Pharmaceuticals, Inc., a ... therapies for infectious diseases, announced today the addition ... recognized key opinion leader in the areas of ... board. Founder and Chief Executive Officer, ... Dr. Opal,s extensive experience investigating bacterial toxins and ...
Breaking Medicine Technology:Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... WIRE)--Apr 19, 2007 - King,Pharmaceuticals, Inc. (NYSE:KG) ... results from the Phase III clinical trial,evaluating ... ALTACE(R),(ramipril) diuretic fixed-dose combination product. The Company ... expects to present the,findings in detail at ...
... AACR Highlight Progress in SuperGen's,Oncology-Focused Pre-Clinical Pipeline, ... SuperGen,Inc. today announced that MP470, its multi-targeted ... critical component of,double- stranded DNA repair in ... of,presentations at the 2007 American Association for ...
Cached Medicine Technology:King Pharmaceuticals Announces Plan to Report Positive Data from,Phase III Clinical Trial Evaluating the Combination of Altace with,Hydrochlorothiazide 2Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 2Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 3Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 4Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 5Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 6Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 7
(Date:11/27/2014)... Blood-borne pathogens raise the risk of spreading diseases, ... place to counter this. However, it doesn’t seem as ... menstrual blood are taken as seriously. , "This ... to handle tampons and menstrual pads while also protecting ... He then created a prototype of the Sani-M, an ...
(Date:11/27/2014)... 2014 "As a nurse I see ... of urinary incontinence," said an inventor from Whiting, N.J. ... specialized accessory to prevent leakage and keep them dry ... urine leakage. This prevents stains on pants, skirts and ... pad ensures that the individual has time to get ...
(Date:11/27/2014)... HealthDay Reporter , WEDNESDAY, Nov. 26, 2014 (HealthDay ... second language, new research suggests. But anyone who tries to ... boost, the small study finds. The brain "becomes ... Li, co-director of the Center for Brain, Behavior and Cognition ... said, that "the brain networks of the more successful learners ...
(Date:11/27/2014)... Dennis Thompson HealthDay Reporter ... experimental Ebola vaccine appears to be safe and produces an ... virus, according to early clinical trial results reported by the ... phase I clinical trial for the vaccine paves the way ... Liberia and Sierra Leone as early as January, said Dr. ...
(Date:11/27/2014)... November 27, 2014 In order to enable ... Sharpes, Fla., designed an easy way to avoid touching a ... He then created a prototype of the patent-pending Toilet Tamer, ... a toilet seat and/or lid in a more sanitary manner. ... spread of germs. Overall, it promotes good hygiene and peace ...
Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3
... infections occuring more often than previously believed, study finds ... drug-resistant staph infections are more common, both in and ... study warns. , Methicillin-resistant Staphylococcus aureus (MRSA) infections are ... among people in hospitals and can result in severe ...
... Even though Americans pick up their,toothbrushes for a ... cleaning of their own. Celebrity Dentist Dr. Bill Dorfman ... survey conducted by the,Philips Sonicare brand shows dirty brushes ... this report from Philips (NYSE: PHG ) at:, ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), the ... today announced that it has,scheduled a conference call and ... ET to discuss operating results for the third quarter ... issue its financial news,release the morning of November 1 ...
... Request Highlights December 2 Annual Wells Fargo Walk of Ages ... ... is,inviting everyone with the name of "Walker" in the United States to either,join ... of,Ages" on December 2 in Reseda. According to official census records there,are 663,233 ...
... Oct. 16 Young Innovations, Inc.,(Nasdaq: YDNT ) ... results with a live and on-demand web cast conference ... Time. A live audio,broadcast of the call will be ... live audio broadcast,will also be available through the Company,s ...
... SYMBOL - BCL.P, VANCOUVER, Oct. 16 ... to announce that it has entered into ... 2007 (the "Arrangement,Agreement") with iCo Therapeutics Inc. ... will constitute Beanstalk,s,"Qualifying Transaction" as a capital ...
Cached Medicine News:Health News:Drug-Resistant Staph a Widespread Threat 2Health News:Drug-Resistant Staph a Widespread Threat 3Health News:Gentiva(R) Health Services Schedules Third Quarter Earnings Call and Web Cast for Thursday, November 1, 2007 2Health News:Gentiva(R) Health Services Schedules Third Quarter Earnings Call and Web Cast for Thursday, November 1, 2007 3Health News:FORGET THE JONESES, This is All About Keeping up With the Walkers as the Los Angeles Jewish Home Sends Out an Invite to Everyone Named 'Walker' in the United States 2Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 2Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 3Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 4Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 5Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 6Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 7Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 8Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 9Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 10
... temporary internal drainage from the ... Supplied sterile in peel-open packages. ... Periodic evaluation is advised; polyurethane, ... not remain indwelling more than ...
... for temporary internal drainage from ... bladder. Supplied sterile in peel-open ... CAUTION: Periodic evaluation is advised; ... must not remain indwelling more ...
... Used for catheter or instrument introduction. ... to be peeled away and removed. ... or instrument to be introduced should ... through the sheath. Supplied sterile in ...
... Used to provide ... or epispadias repair. The ... to partially close during ... urethra while maintaining urethral ...
Medicine Products: